RISA Labs, Inc.

RISA Labs, Inc. develops AI-driven workflow automation solutions focused on enhancing efficiency in oncology clinical operations, particularly in prior authorization processes to improve patient care and operational effectiveness. Founded in 2024 in San Francisco, US, RISA Labs, Inc. provides advanced automation solutions for oncology.

The company raised USD 11. 1 million in its series A round on January 12, 2026, co-led by Cencora Ventures and Optum Ventures, with participation from Oncology Ventures and Z21 Ventures. RISA Labs was established by a team with experience in healthcare technology but specific founder details are not available. RISA Labs specializes in AI-powered workflow automation solutions aimed at optimizing prior authorization processes within oncology clinical operations.

The core offering focuses on intelligent automation that streamlines eligibility checks, medical necessity verification, and prior authorization submissions, effectively mitigating treatment delays for cancer patients. Designed to facilitate operational efficiency, these solutions are utilized by healthcare providers, including hospitals and oncology clinics, allowing their staff to concentrate more on patient care rather than administrative tasks. RISA Labs serves a diverse clientele primarily across the United States, addressing the critical challenges in oncology care caused by fragmented prior authorization processes. Their technology integrates seamlessly with existing healthcare systems, catering to oncology sub-specialties such as medical oncology, surgical oncology, and hematology oncology, among others.

RISA Labs generates revenue through a subscription-based model for its workflow automation solutions, which are tailored for oncology practices and healthcare organizations. Clients typically engage in contracts that allow access to the platform, which includes features like auto-populating payer-specific forms and real-time authorization verification. The transactions occur directly between RISA Labs and healthcare providers, ensuring that organizations can optimize their prior authorization processes with minimal disruption. This direct-to-business approach fosters long-term partnerships and sustained revenue streams, particularly as healthcare providers increasingly seek efficient solutions to combat care delays.

While specific pricing details for the services are not disclosed, the offerings are designed to provide a comprehensive solution for various types of oncology-related prior authorizations. In January 2026, RISA Labs, Inc. raised USD 11. 1 million in series A funding to scale its artificial intelligence operating system for oncology across cancer centres, health systems, specialty pharmacies, and infusion networks nationwide.

The funding will support the company in launching new products aimed at enhancing automation capabilities, with plans to introduce these innovations in the next 12 months. RISA Labs intends to expand into new markets, specifically targeting oncology centers across North America and Europe by the end of 2026.